Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

BACKGROUND: Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Peter C., Saurigny, Didier, Vencovsky, Jiri, Takeuchi, Tsutomu, Nakamura, Tadashi, Matsievskaia, Galina, Hunt, Barbara, Wagner, Thomas, Souberbielle, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471864/
https://www.ncbi.nlm.nih.gov/pubmed/30999929
http://dx.doi.org/10.1186/s13075-019-1879-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471864/
https://www.ncbi.nlm.nih.gov/pubmed/30999929
http://dx.doi.org/10.1186/s13075-019-1879-x

Ejemplares similares